Skytron, LLC — FDA Warning Letter, 2026-05-19: Medical Device/Adulterated/Misbranded/Lacks PMA and/or 510(k)
Letter issued · posted to fda.gov .
Subject as published: Medical Device/Adulterated/Misbranded/Lacks PMA and/or 510(k)
TL;DR
The FDA issued a warning letter to Skytron, LLC (CEO David Mehney) on May 19, 2026, regarding four products—1140 Sentry, 2280 Syndicate, 3200 Max, and UV Smart D25—marketed in the United States without required premarket approval (PMA) or 510(k) clearance, violating the Federal Food, Drug, and Cosmetic Act. The agency determined the devices are adulterated and misbranded; the UV Smart D25 is additionally misbranded because its marketing materials reference FDA registration in a manner that creates a misleading impression of official FDA approval. The FDA also found that the UV Smart D25 fails to qualify for the 510(k) exemption claimed under 21 CFR 880.6992 (medical washer-disinfectors) because it uses UVC radiation without a mechanical cleaning step, differing from the exempt device category's required functional design.
Argus analysis
# FDA Warning Letter Analysis: Skytron, LLC
**Company and Violations**
Skytron, LLC, based in Grand Rapids, Michigan, received a warning letter from FDA's Center for Devices and Radiological Health on May 19, 2026, for marketing four ultraviolet-C (UVC) disinfection devices without required regulatory clearance. The devices in question—the 1140 Sentry, 2280 Syndicate, 3200 Max, and UV Smart D25—are marketed for disinfecting healthcare environments and medical equipment. FDA determined these products are medical devices because they are intended to prevent disease or affect bodily functions, yet the company distributed them without premarket approval or 510(k) clearance.
**Regulatory Citations and Meaning**
The violations cite three primary regulatory deficiencies. Section 501(f)(1)(B) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. § 351) addresses adulteration—the devices lack required premarket approval (PMA) or investigational device exemption (IDE). Section 502(o) (21 U.S.C. § 352) addresses misbranding related to missing 510(k) premarket notification under 21 CFR 807.81. Additionally, the UV Smart D25 violated section 502(a) through misleading FDA registration statements. Notably, while the UV Smart D25 was registered under 21 CFR 880.6992 (medical washer-disinfector exemption), FDA determined it does not qualify because it uses only UV-C radiation without the mechanical cleaning or thermal/chemical disinfection steps the exemption requires.
**Timeline and Industry Monitoring**
Skytron's correspondence history spans from February 2022 through July 2024, showing repeated FDA requests to remove healthcare-related claims. The company committed to compliance in March 2024 but allegedly failed to fully comply by July 2024, triggering this warning letter. Compliance officers should monitor whether Skytron submits 510(k) premarket notifications, removes marketing claims, or initiates product recalls. Industry peers should note that FDA scrutinizes marketing language closely—claims about disease prevention or healthcare facility use trigger device classification, regardless of registration status under different regulatory categories.
Severity context
Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
Regulatory background
Medical device Warning Letters typically combine QSR observations (21 CFR Part 820) with adulteration (21 USC 351) or misbranding (21 USC 352). Post-market surveillance and MDR reporting (21 CFR Part 803) are recurring subjects.
What peer compliance teams typically do next
Most compliance officers at peer companies use a Warning Letter against a named entity as a checklist for their own CAPA program. Common steps: pull the verbatim FDA letter; map each cited 21 CFR section against the team’s SOP library; confirm CAPA coverage; brief the QMR (Quality Management Review) on whether the cited subject matter is in scope for the next internal audit. The 15-business-day response window applies to the cited entity, not to peers — but a documented internal review against the cited subjects is what regulators expect to see if a peer is later inspected on the same topic.
Excerpt from the FDA Warning Letter (public domain, 17 USC §105)
WARNING LETTER Skytron, LLC MARCS-CMS 723950 — May 19, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Product: Medical Devices Recipient: Recipient Name David Mehney Recipient Title CEO Skytron, LLC 5085 Corporate Exchange Blvd SE Grand Rapids , MI 49512 United States (b)(6)@Skytron.com Issuing Office: Center for Devices and Radiological Health United States WARNING LETTER May 19, 2026 Dear David Mehney, The United States Food and Drug Administration (FDA or agency) has learned that your firm is marketing the 1140 Sentry, 2280 Syndicate, 3200 Max and UV Smart D25 in the United States without marketing clearance or approval, in violation of the Federal Food, Drug, and Cosmetic Act (the Act). Under section 201(h) of the Act, 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body. FDA has reviewed your firm’s webpages at https://www.skytron.com/infection-prevention-technologies/, https://www.skytron.com/wp-content/uploads/documentation/UVC-Correctional-Disinfection-REV3-WEB.pdf and UV-Smart-D25-Brochure-WEB.pdf and has determined that the 1140 Sentry, 2280 Syndicate, 3200 Max, and UV Smart D25 devices are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g) for the devices as described and marketed. The 1140 Sentry, 2280 Syndicate, 3200 Max, and UV Smart D25 devices are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm introduced or delivered for introduction into interstate commerce for commercial distribution these devices without submitting a premarket notification to FDA as required by section 510(k) of the Act, 21 U.S.C. § 360(k), and 21 CFR 807.81. The UV Smart D25 device is further misbranded under section 502(a) of the Act, 21 U.S.C. § 352(a) because of your misleading references, identified in the quoted statements below, to your firm’s registration. Your brochure for that device references that product’s FDA registration in the context of “use[] to clean non-invasive medical equipment,” which creates an impression of official FDA approval, clearance, authorization, or endorsement or other evaluation of your products that is misleading and constitutes misbranding. See 21 CFR 807.39. In addition, although there is a 510(k) exemption for medical washer-disinfector devices under 21 CFR 880.6992, which is the regulation (and product code MEC) under which you registered the UV Smart D25 device, the device is not exempt because it is not the type of device that is within the generic categor…
Excerpt only. The full verbatim Warning Letter is the source of truth — always read the original before regulatory decisions.
The verbatim FDA Warning Letter is the source of truth. Always read the original before acting on any analysis or summary on this page.
Read the full letter on fda.gov ↗Frequently asked questions
- What is the standard FDA response window for a warning letter?
- FDA warning letters typically require a written response within 15 working days of receipt, outlining the corrective and preventive actions the company will take.
- Has Skytron, LLC had FDA enforcement actions before?
- This is the only FDA Warning Letter Argus HQ has on file for Skytron, LLC as of 2026-07-07. Argus ingests new FDA enforcement records daily.
- What FDA violations was Skytron, LLC cited for?
- The FDA Warning Letter to Skytron, LLC (issuing office: Center for Devices and Radiological Health) cites: Medical Device/Adulterated/Misbranded/Lacks PMA and/or 510(k). Classification: Medical device.
- When did FDA issue the warning letter to Skytron, LLC?
- FDA issued the letter (MARCS-CMS 723950) on 2026-05-19 and posted it publicly on fda.gov on 2026-07-07.
argus.hq
Don’t find out about the next one six weeks late.
Argus reads every FDA Warning Letter the day it publishes, summarizes it against your watchlist, and lands the ones touching your business in your inbox at 6am ET. $199/month. Cancel any time.
methodology
The analysis above is produced by Anthropic Claude Haiku 4.5 against the verbatim FDA Warning Letter excerpt and is brand-voice lint-checked before publish. The TL;DR is the same summary that ships in the customer email digest. Severity is auto-classified by Argus from the subject string and letter body using rules documented in lib/ingestion/fda-warning-letters.ts.
Argus HQ is informational only. Summaries and analyses are AI-generated and may contain errors, misclassifications, or omissions. Verify against the FDA source URL above. Argus HQ is not a law firm, accounting firm, or regulatory agency, and provides no legal, accounting, financial, medical, or regulatory advice.
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). Skytron, LLC — FDA Warning Letter, 2026-05-19: Medical Device/Adulterated/Misbranded/Lacks PMA and/or 510(k). Digital Empire LLC. Retrieved from https://argushq.ai/fda/warning-letter/fda-wl-skytron-llc-2026-05-19-medical-device
"Skytron, LLC — FDA Warning Letter, 2026-05-19: Medical Device/Adulterated/Misbranded/Lacks PMA and/or 510(k)." Argus HQ Research, Digital Empire LLC, 2026, argushq.ai/fda/warning-letter/fda-wl-skytron-llc-2026-05-19-medical-device.
Argus HQ Research. "Skytron, LLC — FDA Warning Letter, 2026-05-19: Medical Device/Adulterated/Misbranded/Lacks PMA and/or 510(k)." Digital Empire LLC. Accessed July 13, 2026. https://argushq.ai/fda/warning-letter/fda-wl-skytron-llc-2026-05-19-medical-device.
@misc{argushq_argushq_ai_fda_warning_letter_fda_wl_skytron_llc_2026_05_19_medical_device_2026,
title = {Skytron, LLC — FDA Warning Letter, 2026-05-19: Medical Device/Adulterated/Misbranded/Lacks PMA and/or 510(k)},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire LLC},
url = {https://argushq.ai/fda/warning-letter/fda-wl-skytron-llc-2026-05-19-medical-device},
note = {Accessed: July 13, 2026}
}